Clinical trials: Neuromuscular Monitoring
Ischaemic Stroke
The RETRAIN Trial Phase 2
Ischaemic strokes, caused by a disruption in the brain's blood supply, are the second leading cause of death and disability in the United Kingdom.
- Trial name
- RETRAIN 2 (NCT07197996)
- Testing
- Intermittent Pneumatic Compression, geko® T3
- Where
- United Kingdom
- Volunteers
- 53 people
- Sponsor
- Firstkind Ltd
Neuromuscular Diseases, Scoliosis
Evaluation of the Feasibility of Remote Monitoring of Mechanical In-exsufflation Devices in Paralytic and Neuromuscular Patients Treated at Home.
The implementation of an mechanical in-exsufflator device (MI-E) requires specific expertise because it is a complex device that requires fine-tuning of the settings according to different clinical situations to optimize its…
- Trial name
- TELE-INEX (NCT05723289)
- Testing
- MI-E Telemonitoring
- Where
- France
- Volunteers
- 10 people
- Sponsor
- KerNel Biomedical
Respiratory Failure, Neuromuscular Disease
Ventilator Monitoring in Early Exacerbation Detection
The aim of this study is to determine whether respiratory disease exacerbations (a sudden worsening of symptoms) can be predicted by variables that are monitored by non-invasive ventilators (small machines that assist breathing)…
- Conditions
- Respiratory Failure, Neuromuscular Disease, Chest Wall Disorder, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01644162
- Testing
- iVAPS ventilation
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- ResMed
ICU Acquired Weakness
Safety and Efficacy of the MyokinE100 (CL-EMS Alpha) Device in Inducing Visible Muscle Contraction in Healthy Volunteers
Every patient admitted to the Intensive Care Unit (ICU) is at risk of developing "Intensive Care Unit Acquired Weakness" (ICUAW).
- Trial name
- NCT06023511
- Testing
- Electrical muscle stimulation
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Health Discovery Labs
Amyloid Cardiomyopathy, Transthyretin-Related
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
- Trial name
- AG10 (NCT04988386)
- Testing
- Acoramidis (AG10)
- Where
- 72 sites in United States, Australia and 15 more
- Volunteers
- 389 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Myasthenia Gravis, Myasthenia Gravis, Generalized
Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis
Evaluate the feasibility of using digital health technologies to monitor symptoms in myasthenia gravis (MG). Study subjects will be screened and enrolled at Massachusetts General Brigham Hospital to participate in this 12 month…
- Trial name
- BioDigit MG-02 (NCT07224386)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- BioSensics
Generalized Myasthenia Gravis, gMG
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine…
- Trial name
- OCTAGON (NCT07221838)
- Testing
- Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone
- Where
- 12 sites in United States, Germany and 2 more
- Volunteers
- 75 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Neuromuscular Blockade Monitoring, NMT
NMT EasyFit Sensor and Cable
The purpose of this clinical study is to collect and assess feedback from clinical users regarding the functionality and device use and collection of raw parameter date from the NMT Sensor and NMT Cable.
- Trial name
- NCT07394140
- Testing
- Collection of NMT Technology
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GE Healthcare
Invasive Group B Streptococcus Disease, Group B Streptococcus
Comprehensive Outcomes Monitoring for Peri- and Postnatal Invasive Group B Strep Sequelae (COMPPASS) Registry
The goal of this registry is to collect and store important medical and non-health information on children from 0 to 18 years of age affected by early- (up to 24 hours after birth) and late-onset (up to 90 days after birth)…
- Conditions
- Invasive Group B Streptococcus Disease, Group B Streptococcus, Group B Streptococcal Infection, Group B Streptococcus (GBS) Disease
- Trial name
- COMPPASS (NCT06896526)
- Volunteers
- 10,000 people
- Sponsor
- Precia Group
Peripheral Nerve Injuries
Continuous Observational Monitoring Program for Allay™ Hydrogel Cap Safety and Success Study
is is a multi-center, open-label, observational registry study (both prospective and retrospective) designed to evaluate the safety and performance of the allay™ Hydrogel Cap.
- Trial name
- COMPASS (NCT07246980)
- Testing
- Nerve Cap
- Where
- 5 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Tulavi Therapeutics,Inc.
Chronic Inflammatory Demyelinating Polyneuropathy
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic demyelinating polyneuropathy of autoimmune origin with a progressive or relapsing course.
- Trial name
- HELIPAD 1 (NCT03779828)
- Testing
- HOME LINK
- Where
- 10 sites in France
- Volunteers
- 11 people
- Sponsor
- CSL Behring
Polio
Immunogenicity of After Primary Immunization and Booster Immunization of sIPV
This study was conducted on the basis of "Safety Observation of Sabin Strain Inactivated Polio Vaccine (Vero Cell) on primary Immunization, Booster Immunization and Simultaneous Vaccination with Other Vaccines in Infants and…
- Trial name
- NCT06058429
- Testing
- no intervention
- Where
- China
- Volunteers
- 233 people
- Sponsor
- Sinovac Biotech Co., Ltd
Fibromyalgia
Tool for Fibromyalgia Diagnosis and Effect of Extra Virgin Olive Oil
PRONACERA THERAPEUTICS S.L. is a young biotechnological company focused on the development of genetic diagnostic tools and treatments for pathologies in different medical areas such as reproduction, fibromyalgia and rare diseases…
- Trial name
- FIBROKIT (NCT05921409)
- Testing
- Extra Virgin Olive oil-supplemented Mediterranean Diet Intervention, Olive oil-supplemented Mediterranean Diet Intervention
- Where
- Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Pronacera Therapeutics SL
Neuromuscular Monitoring After Administration of Neuromuscular Blocking Agents in Different Types of Surgery
Observational Study to Evaluate the Current Neuromuscular Monitoring Practice Used After Different Types of Surgery, for Which Neuromuscular Blocking Agents Were Used, With or Without Blocking Reversal (P06556)
The intent of this observational study is to collect prospective data regarding neuromuscular monitoring practices and extubation standards (Train-Of-Four [TOF] value) during surgery, in countries of Central and Eastern Europe…
- Trial name
- NCT01213264
- Testing
- No neuromuscular blockade (NMB)-reversal agent used, Sugammadex, Other NMB-Reversal Agents Used in Routine Anesthesiology Practice
- Volunteers
- 659 people
- Sponsor
- Merck Sharp & Dohme LLC
Transthyretin Amyloidosis, Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
National, multicenter, epidemiological, longitudinal protocol to investigate the hATTR prevalence in an at-risk population for Hereditary Transthyretin Amyloidosis (hATTR) and subjects diagnosed with hATTR, to monitor the…
- Conditions
- Transthyretin Amyloidosis, Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Polyneuropathies
- Trial name
- TRAMmoniTTR (NCT03237494)
- Where
- 84 sites in Austria, Germany and 1 more
- Volunteers
- 5,028 people
- Sponsor
- CENTOGENE GmbH Rostock
Amyloid Cardiomyopathy
Open-Label Study of AG10 in Patients With Cardiomyopathy
This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of acoramidis administered on a background of stable heart failure therapy.
- Trial name
- NCT03536767
- Testing
- Acoramidis
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Fibromyalgia
A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring
The study is designed to accurately assess any changes in blood pressure and pulse at 100 and 200 mg daily dose of milnacipran in patients with fibromyalgia syndrome.
- Trial name
- NCT00618956
- Testing
- Milnacipran hydrochloride
- Where
- 38 sites in United States
- Volunteers
- 321 people
- Sponsor
- Forest Laboratories
Sarcopenia, Frailty
BandPass: A Remote Monitoring System for Sarcopenia and Functional Decline Phase II Aim 4
This study evaluates a home-based strengthening program supported by the BandPass system, which includes a Bluetooth-enabled resistance exercise band, a mobile app that provides real-time feedback, and a clinician dashboard for…
- Trial name
- NCT07421648
- Testing
- BandPass System
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- SynchroHealth LLC
Compartment Syndrome
Study of New Catheter & Pressure Monitor System to Help Prevent Compartment Syndrome From Developing in the Injured Leg
An investigation of a new catheter and pressure monitor system that may help to prevent a complication called compartment syndrome from developing in an injured leg.
- Trial name
- TS2 (NCT00681616)
- Testing
- Compartment Monitoring System (CMS), Compartment Monitoring System with Active Fluid Removal, Compartment Monitoring System without fluid removal
- Where
- 13 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Twin Star Medical, Inc.
Autosomal Dominant Hypocalcemia
ADH1 and ADH2 Disease Monitoring Study (DMS)
A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease…
- Trial name
- CLARIFY (NCT05227287)
- Where
- 27 sites in United States, Australia and 11 more
- Volunteers
- 95 people
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company